[ E-scape Bio raises $63M in Series A ]
E-scape Bio has raised $63 million in Series A funding.
Founded in 2015, E-scape Bio is a biopharmaceutical company focused on the discovery and development of small-molecule drugs to treat genetically-defined subpopulations in neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.
The company’s therapeutic programs are designed to restore normal function disrupted by inherited genetic mutations causing the disease.
|City||San Francisco, California|
|Founder / CEO||/|
|Investors||Sutter Hill Ventures|
|Osage University Partners|
|Novartis Venture Fund|
|Johnson & Johnson Innovation|